Clinical trials: Behavioral Disorder
Attention-Deficit/Hyperactivity Disorder
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
To assess the efficacy of optimized Extended-release Guanfacine Hydrochloride compared with placebo in the treatment of adolescents aged 13-17 years with a diagnosis of ADHD as measured by the ADHD-RS-IV
- Trial name
- NCT01081132
- Testing
- Extended-release Guanfacine Hydrochloride
- Where
- 54 sites in United States
- Volunteers
- 314 people
- Sponsor
- Shire
Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection
Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed Dyslipidemia
The study is divided into 2 parts. The first part of the study will be double-blinded and will last for 24 weeks. During this time, participants will be randomized in a ratio of 2:1 to receive either evolocumab once monthly (QM)…
- Trial name
- NCT02833844
- Testing
- Evolocumab
- Where
- 78 sites in United States, Australia and 13 more
- Volunteers
- 467 people
- Sponsor
- Amgen
Chronic Insomnia
A Remote, 9-week Insomnia Treatment Trial to Collect Real World Data for a Digital Therapeutic
The purpose of the study is to collect data in a real-world environment, for a digital therapeutic that delivers CBT-I through a decentralized clinical trial, open to participants with chronic insomnia.
- Trial name
- DREAM (NCT04325464)
- Testing
- PEAR-003A
- Where
- United States
- Volunteers
- 1,590 people
- Sponsor
- Pear Therapeutics, Inc.
Attention Deficit Disorder With Hyperactivity
Safety and Efficacy of SPD503 in Treating ADHD in Children and Adolescents Aged 6-17
The purpose of this study is to determine the efficacy of SPD503 compared to placebo in the treatment of children and adolescents aged 6-17 with ADHD.
- Trial name
- NCT00150618
- Testing
- SPD503 (1 mg), SPD503 (2 mg), SPD503 (3 mg)
- Volunteers
- 324 people
- Sponsor
- Shire
Depressive Episodes, Bipolar I Depression
A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder.
A clinical trial to study the efficacy and safety of an investigational drug in people with major depressive episodes associated with with Bipolar I disorder (bipolar I depression) Participants in the study will either receive…
- Trial name
- NCT05169710
- Testing
- SEP-4199 CR 200 mg, SEP-4199 CR 400 mg
- Where
- 89 sites in United States, Bulgaria and 4 more
- Volunteers
- 83 people
- Sponsor
- Sumitomo Pharma America, Inc.
Suicide, Mental Health Disorder
Optimizing a Just-in-time Adaptive Intervention for Suicide Safety Planning in Adolescents
Despite efforts to prevent suicide, US rates are climbing, and suicide is the second leading cause of death amongst youth. Digital tools, especially personal smartphones, are promising avenues to address these issues and can be…
- Conditions
- Suicide, Mental Health Disorder, Anhedonia
- Trial name
- NCT06665620
- Testing
- ViraBrite nudges
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Ksana Health
Infertility, Ovulation Induction
SJ-0021 (Gonalef®) Versus Purified Pituitary Gonadotropin (Fertinorm-P®) for Ovulation Induction in Japanese Infertile Women
Efficacy and safety studies in the past have suggested that a starting dose of 75 International Unit (IU) of SJ-0021, and an increase in the dose by 37.5 IU every 7 days, are safe for treatment of subjects with ovulatory…
- Trial name
- NCT01185782
- Testing
- Gonalef® (Follitropin alfa), Purified pituitary gonadotropin (Fertinorm-P®)
- Where
- Japan
- Volunteers
- 300 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Asthma
Assessment of a Mobile Intervention to Increase Adherence to Asthma Medication Among Adolescents
The purpose of this study is to assess the use of a mobile health intervention to improve adherence to asthma medication among adolescents.
- Trial name
- NCT02426814
- Testing
- Inhaler sensor, Mobile application for asthma adherence
- Where
- United States
- Sponsor
- CoheroHealth
Sleep Hygiene, Sleep Disturbance
Effects of a Novel Supplement on Sleep, Metabolism, Body Composition and Performance
This study aimed to investigate the effects of a novel dietary supplement, consisting of melatonin and magnesium in a pod (coffee machine capsule) format, on sleep quality, stress, mood, sleepiness, biological rhythms…
- Trial name
- 4BETTSLEEP (NCT05236504)
- Testing
- Melatonin and magnesium-containing pod
- Where
- Portugal
- Volunteers
- 35 people
- Sponsor
- Bettery S.A.
Major Depressive Disorder
A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder
This is a multicenter, Phase 2, double-blind, randomized, parallel-arm, placebo-controlled clinical trial to evaluate the efficacy, safety, and tolerability of XEN1101 in subjects with Major Depressive Disorder.
- Trial name
- X-NOVA (NCT05376150)
- Testing
- XEN1101 10 mg, XEN1101 20 mg
- Where
- 20 sites in United States
- Volunteers
- 168 people
- Sponsor
- Xenon Pharmaceuticals Inc.
Depression
Fevarin® Effectiveness in Treatment of Depression in Patients With Neurological Disorder
Prospective, multicenter, non-comparative, observational program to describe prevalence of depressive symptoms in a variety of neurological disorders and effects of Fevarin® on the severity of anxiety and depression, sleep state…
- Trial name
- FRIENDS (NCT02043197)
- Where
- 29 sites in Russia
- Volunteers
- 300 people
- Sponsor
- Abbott
Smoking Cessation, Harm Reduction
Assisting Smokers to Switch to a JUUL E-Cigarette by Devaluing Combustible Cigarettes
This study will evaluate a reward devaluation strategy in which smokers use the JUUL e-cigarette immediately before any combustible cigarettes (CCs) are smoked.
- Conditions
- Smoking Cessation, Harm Reduction, E-Cig Use, Cigarette Smoking
- Trial name
- RECON (NCT04188197)
- Testing
- JUUL
- Where
- 2 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Rose Research Center, LLC
Trichotillomania
A Study in Patients With Trichotillomania
The purpose of this study is to explore the safety, tolerability and activity of SXC-2023 when dosed for 6 weeks versus placebo in adult patients with moderate to severe Trichotillomania.
- Trial name
- TTM (NCT03797521)
- Testing
- SXC-2023
- Where
- 13 sites in United States
- Volunteers
- 128 people
- Sponsor
- Promentis Pharmaceuticals, Inc.
Attention Deficit/Hyperactivity Disorder
A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder.
To evaluate long-term safety exposure
- Trial name
- NCT05279313
- Testing
- Centanafadine Hydrochloride
- Where
- 86 sites in United States, Canada and 1 more
- Volunteers
- 680 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Attention Deficit Hyperactivity Disorder
Atomoxetine vs Placebo in the Treatment of ADHD in Swedish Children and Adolescents
Comparison of the effect of Atomoxetine and psychoeducation with placebo and psychoeducation after 10 weeks of treatment
- Trial name
- NCT00191542
- Testing
- Atomoxetine
- Where
- 9 sites in Sweden
- Volunteers
- 100 people
- Sponsor
- Eli Lilly and Company
Depression, Major Depressive Disorder
Relapse-Prevention Study With Levomilnacipran ER (F2695 SR) in Patients With Major Depressive Disorder
The purpose of this study is to evaluate the safety and efficacy of Levomilnacipran ER relative to placebo in the prevention of depression relapse in patients with major depressive disorder (MDD).
- Trial name
- NCT01085812
- Testing
- Levomilnacipran ER
- Where
- 35 sites in United States, Canada
- Volunteers
- 734 people
- Sponsor
- Forest Laboratories
Attention Deficit Hyperactivity Disorder
Dasotraline Pediatric Extension Study
This is an open label 26 week extension study for subjects who completed SEP360-202.
- Trial name
- NCT02457819
- Testing
- Dasotraline
- Where
- 36 sites in United States
- Volunteers
- 237 people
- Sponsor
- Sumitomo Pharma America, Inc.
Hearing Loss
Evaluating an Audiology Text-Message Protocol to Support Hearing Aid Use in NHS Adult Audiology Patients
Over 18 million adults in the United Kingdom have significant hearing loss, linked to isolation, depression and comorbidities. Hearing aids are the main management option yet are frequently unused (~23%) or used irregularly…
- Trial name
- NCT07146607
- Testing
- Audiology text-message protocol
- Where
- 3 sites in United Kingdom
- Volunteers
- 70 people
- Sponsor
- WSAUD A/S
Bone Conduction, Hearing Loss, Conductive
Post-market Evaluation of the Transition From the Baha Connect System to the Osia System in Adult Bone Conduction Implant Recipients
The goal of this interventional study is to confirm the safety and performance of the latest generation Osia System and to examine its benefits compared to the Baha Connect System in adults with mixed or conductive hearing loss…
- Conditions
- Bone Conduction, Hearing Loss, Conductive, Hearing Loss, Mixed
- Trial name
- OSIRIS (NCT07130136)
- Testing
- Cochlear™ Osia® System, Cochlear™ Baha® System
- Where
- 3 sites in United Kingdom
- Volunteers
- 20 people
- Sponsor
- Cochlear
ADHD
Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)
This study is a Phase 3, multi-center, randomized, 6-week, double-blind, placebo-controlled, parallel-group trial to assess the efficacy and safety of solriamfetol in adolescents aged 12 to <18 years with ADHD.
- Trial name
- NCT07717892
- Testing
- Solriamfetol Dose A, Solriamfetol Dose B
- Where
- 28 sites in United States
- Volunteers
- 468 people
- Sponsor
- Axsome Therapeutics, Inc.